BNET Industries
- Private
- CA
Dow Jones Description
Only 30 minutes from the heart of downtown Vancouver, the University of British Columbia holds an international reputation for excellence in advanced research and learning. The spectacular UBC campus is a 'must-see' for any visitor to the city -- where snow-capped mountains meet ocean, and breathtaking vistas greet you around every corner. The university boasts some of the city's best attractions & recreation facilities, including the Museum of Anthropology, the Chan Centre for the Performing Arts, the UBC Botanical Garden and Centre for Plant Research, and endless opportunities to explore forested trails in the adjoining 763-hectare Pacific Spirit Regional Park.
Contact Information
2329 West Mall
Vancouver, British Columbia V6T 1Z4
604.822.2211
NAICS Code Colleges, Universities, and Professional Schools: 611310
Recent Events
-
UBC GETS LARGE, MYSTERIOUS DONATION
News & Analysis
Filter by
healthcare and university of british columbia - All News and Analysis
MIV Therapeutics to Present at the BMO Capital Markets Focus on Healthcare Conference
MIV Therapeutics, Inc. (OTCBB: MIVT) (FRANKFURT: MIV), a leading developer of next-generation coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, today announced that Dr. Mark Landy, president of MIV Therapeutics, will present a company overview at the BMO Capital Markets Focus On Healthcare Conference...
EnWave Files bioREV Equipment and Methodology Patent for Vaccine Dehydration.
VANCOUVER, BRITISH COLUMBIA, Sep 14, 2007 CCNMatthews via COMTEX -- EnWave Corporation (TSX VENTURE:ENW)(FRANKFURT:E4U) ("EnWave" or "the Company") wishes to report that Dr. Tim Durance and EnWave Senior Engineer Leon Fu have filed a US patent application on behalf of EnWave to protect the Company's ...
WebAlert: MIV Therapeutics Investor Conference Call Starts Today at 11 AM EDT
President to Update Investors on Major Strategic Achievements and Plans for the Remainder of 2007 ATLANTA -- MIV Therapeutics Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, will host a live conference call with...
EnWave Corporation: Vaccine, Drug Process Patents Filed.
VANCOUVER, BRITISH COLUMBIA, Feb 22, 2007 CCNMatthews via COMTEX -- EnWave Corporation (TSX VENTURE:ENW) (the "Company") wishes to report that Dr. Tim Durance, in conjunction with other researchers at the University of British Columbia UBC, has filed US CIP and international PCT patent applications to protect...
MIV Therapeutics to Present Advanced Biocompatible Stent-Coating Technology at International Biomaterials Conference; Senior Scientist Invited to Review Data at 19th International Symposium on Ceramics in Medicine in China
ATLANTA -- MIV Therapeutics (OTCBB:MIVT)(FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, is scheduled present the highly encouraging development progress of the Company's Hydroxyapatite HAp coatings for coronary stents and other devices at the 19th International Symposium...
BC Mental Health Foundation—Canadian Institute of Health Research Award
604-524-7160 Michelle Bass & Cecilia M. Benoit, Sociology, University of Victoria: The impact of stigma on the mental health of people working in the sex industry. Mandy Yao-Min Chen & Charlotte Johnston, Psychology, University of British Columbia: Effects of paternal attention-deficit/hyperactivity disorder on the outcome of behavioural parent...
MIV Therapeutics Highlights HAp Composite Coating Technologies at Leading Conference on Biomaterials; Better, Safer, More Biocompatible Stent Coating Technologies Presented at Recent International Society of Biomaterials Meeting
VANCOUVER, British Columbia -- MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of new generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, provided detailed background in two scientific poster presentations on its advanced, proprietary coating achievements at the prestigious annual international meeting...
MIV Therapeutics to Highlight Latest HAp Advancements at Leading International Scientific Conference on Biomaterials; MIVT Accepted to Present Proprietary Biocompatible Stent Coating Technology at Society of Biomaterials Meeting
VANCOUVER, British Columbia -- MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of new generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, announced today that it has been accepted to present some of its latest technology achievements at the annual international meeting...
MIV Therapeutics Highlights 2005 Scientific and Strategic Milestones in Development of New Generation Biomedical Technologies; Year-End Report Cites Achievements in Breakthrough Drug Delivery and Other Solutions for Multi-Billion-Dollar Markets
VANCOUVER, British Columbia -- MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems, has reported significant progress in a report outlining the achievement of numerous key strategic, corporate and technological objectives for 2005. "The past year has been a time of...
Meridian Receives Endorsement from Recognised Cardiologist for Digital Pulse Analyzer
SEOUL, Korea -- Meridian Co., Ltd. ("Meridian") (OTCBB:MRDAF) announced today that it has received a positive endorsement of its Digital Pulse Analyzer product from Dr. Saul Isserow. The study performed by Dr. Isserow was undertaken completely independently without any input or influence by any Meridian Co., Ltd....


